Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance

Today's cyclodextrin, ,

Antibody-drug conjugates (ADCs) have begun to fulfill their promise as targeted cancer therapeutics with ten clinical approvals to date. Recently the role that linker-payload reagent design has on the properties of ADCs has been highlighted as an important consideration for developers. In this paper from Abzena, the effect of incorporating hydrophilic macrocycles like cyclodextrin into reagent structures on the in vitro and in vivo behavior of ADCs.

Nick Evans, Ruslan Grygorash, Nicolas Camper, Mark Frigerio, Matthew Bird et al

See the full article here

In vivo assessment of tumor targeting potential of 68Ga-labelled randomly methylated beta-cyclodextrin (RAMEB) and 2-hydroxypropyl-β-cyclodextrin (HPβCD) using positron emission tomography

Today's cyclodextrin, , , , ,

This novel application is a fascinating combination of tumor targeting and diagnosis using of 68Ga-labelled cyclodextrin for positron emission tomography of PGE2-positive tumors.
University of Debrecen – Gabor Opposits, István Jószai, Istvan Kertesz, Zita Képes, Méhes Gábor, Ferenc Fenyvesi István Hajdu, György Trencsenyi

See the full article here

Prostate-specific membrane antigen (PSMA) ligands comprising an amylase cleavable linker

carbohydrates, drug discovery, ,

Using sugars in a prodrug concept is a fascinating idea as these compounds can bring so much to the table like improve stability, PK, or help in targeting. In this patent from Heidelberg University oligosaccharide conjugated prostate-specific membrane antigens are described where the bonds are cleaved by amylase in the body.

See the patent on espacenet